Abstract
Fever is an important early sign of serious treatment-related adverse events such as cytokine release syndrome (CRS) caused by chimeric antigen receptor T cell (CAR-T) immunotherapy and such as infection related to chemotherapy-induced neutropenia ( Oved et al., 2019 Oved J.H. Barrett D.M. Teachey D.T. Cellular therapy: Immune-related complications. Immunol. Rev. 2019; 290: 114-126 Crossref PubMed Scopus (35) Google Scholar ; Freifeld et al., 2011 Freifeld A.G. Bow E.J. Sepkowitz K.A. Boeckh M.J. Ito J.I. Mullen C.A. Raad I.I. Rolston K.V. Young J.A. Wingard J.R. Infectious Diseases Society of AmericaClinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 2011; 52: e56-e93 Crossref PubMed Scopus (1965) Google Scholar ), both events that are commonly experienced by patients with cancer. The standard approach for detecting fever in hospitalized patients is intermittent temperature monitoring, typically every 4–8 h; this could lead to inherent delays in diagnosis of febrile adverse events.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
